Axsome Presents New Data for Solriamfetol in SHARP Study

Axsome is sharing data from a study of solriamfetol in 59 patients with EDS associated with OSA and impaired cognitive function.

Related Keywords

United States ,Germany ,United Kingdom ,Boston ,Massachusetts ,British ,American ,Hans Van Dongen ,Drug Administration ,American Academy Of Neurology ,Us Drug Enforcement Agency On ,Professor At Washington State University ,Axsome Therapeutics ,Cognitive Health ,Apnea Participants During ,Randomized Placebo Controlled ,Annual Meeting ,British Columbia Cognitive Complaints Inventory ,Epworth Sleepiness ,Washington State University ,Enforcement Agency ,